Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting T regulatory cells in autoimmune diseases Toubi EIsr Med Assoc J 2008[Jan]; 10 (1): 73-6Among the several mechanisms that play a role in maintaining peripheral self-tolerance is the existence of a unique CD4+CD25+ population of naturally occurring regulatory T cells, which actively prevent both the activation and the effector function of autoreactive T cells that have escaped different mechanisms of tolerance. Many studies have shown the benefit of targeting this cell population by restoring self-tolerance. Therapies that could possibly increase the suppressive ability of T regulatory cells were proven to improve the course of autoimmune diseases.|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/pharmacology/therapeutic use[MESH]|Autoimmune Diseases/*drug therapy/metabolism[MESH]|Down-Regulation[MESH]|Forkhead Transcription Factors/metabolism[MESH]|Glucocorticoids/pharmacology/therapeutic use[MESH]|Humans[MESH]|Immunoglobulins, Intravenous/pharmacology/therapeutic use[MESH]|Immunologic Factors/pharmacology/therapeutic use[MESH]|Infliximab[MESH]|Interleukin-10/metabolism[MESH]|Lymphocyte Activation/drug effects[MESH]|RNA, Messenger/metabolism[MESH]|Rituximab[MESH]|T-Lymphocytes, Regulatory/*drug effects[MESH]|Tumor Necrosis Factor-alpha/pharmacology/therapeutic use[MESH] |